Maternal Serum Analyte Screening for Fetal Aneuploidy

被引：1
|
作者：
Chasen, Stephen T. [1 ,2 ]
机构：
[1] New York Presbyterian Hosp, New York, NY USA
[2] Weill Cornell Med Coll, New York, NY 10021 USA
来源：
CLINICAL OBSTETRICS AND GYNECOLOGY | 2014年 / 57卷 / 01期
关键词：
serum screening; fetal aneuploidy; Down syndrome; HUMAN CHORIONIC-GONADOTROPIN; FREE BETA-HCG; PLASMA PROTEIN-A; ALPHA-FETOPROTEIN; DOWN-SYNDROME; 1ST TRIMESTER; PAPP-A; NUCHAL TRANSLUCENCY; TWIN PREGNANCIES; 2ND-TRIMESTER;
D O I：
10.1097/GRF.0000000000000017
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
In the first and second trimesters, chemicals produced by the fetoplacental unit are measured to assess risks of fetal abnormalities. Consistent associations between levels of these proteins in such pregnancies enable these biomarkers to be used to calculate risk for Down syndrome and other chromosomal abnormalities in individual pregnancies. Special consideration may be required when assessing risk in multiple pregnancies and pregnancies achieved with infertility therapy.
引用
收藏
页码：182 / 188
页数：7
相关论文
共 50 条
  • [1] Screening for Fetal Aneuploidy: Is Maternal Age Relevant?
    Hawk, Angela F.
    Saller, Devereux N.
    CLINICAL OBSTETRICS AND GYNECOLOGY, 2012, 55 (01) : 217 - 225
  • [2] Fetal Down syndrome screening models for developing countries; Part I: Performance of Maternal Serum Screening
    Wanapirak, Chanane
    Piyamongkol, Wirawit
    Sirichotiyakul, Supatra
    Tongprasert, Fuanglada
    Srisupundit, Kasemsri
    Luewan, Suchaya
    Traisrisilp, Kuntharee
    Jatavan, Phudit
    Tongsong, Theera
    BMC HEALTH SERVICES RESEARCH, 2019, 19 (01)
  • [3] First-trimester maternal serum screening and the risk for fetal distress during labor
    Uccella, Stefano
    Colombo, Giacomo Filippo
    Bulgheroni, Carlo Maria
    Serati, Maurizio
    Bogani, Giorgio
    Salvatore, Stefano
    Ghezzi, Fabio
    Bolis, Pierfrancesco
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2009, 201 (02) : 166.e1 - 166.e6
  • [4] Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency
    de Graaf, IM
    Pajkrt, E
    Bilardo, CM
    Leschot, NJ
    Cuckle, HS
    van Lith, JMM
    PRENATAL DIAGNOSIS, 1999, 19 (05) : 458 - 462
  • [5] Screening for Fetal Aneuploidy
    Rose, Nancy C.
    Mercer, Brian M.
    OBSTETRICS AND GYNECOLOGY, 2016, 127 (05) : E123 - E137
  • [6] Screening for fetal aneuploidy
    Rink, Britton D.
    Norton, Mary E.
    SEMINARS IN PERINATOLOGY, 2016, 40 (01) : 35 - 43
  • [7] First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers
    Spencer, K.
    Staboulidou, I.
    Nicolaides, K. H.
    PRENATAL DIAGNOSIS, 2010, 30 (03) : 235 - 240
  • [8] A re-evaluation of the influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy
    Spencer, K.
    Cowans, N. J.
    Spencer, C. E.
    Achillea, N.
    PRENATAL DIAGNOSIS, 2010, 30 (10) : 937 - 940
  • [9] Ten Years of Experience with First-Trimester Screening for Fetal Aneuploidy Employing Biochemistry from Gestational Weeks 6+0 to 13+6
    Torring, Niels
    Petersen, Olav Bjorn
    Uldbjerg, Niels
    FETAL DIAGNOSIS AND THERAPY, 2015, 37 (01) : 51 - 57
  • [10] Screening for fetal aneuploidy and neural tube defects
    Driscoll, Deborah A.
    Gross, Susan J.
    GENETICS IN MEDICINE, 2009, 11 (11) : 818 - 821
12345